Results 1 to 10 of about 12,973 (166)

Prevalence and Clinical Implications of Pyrazinamide Resistance in Newly Diagnosed TB Patients in Uganda [PDF]

Infection and Drug Resistance
Christopher Ndawula, Nalumaga Pauline Petra, Fredrickson B Wasswa, Joel Bazira Department of Microbiology, Mbarara University of Science and Technology, Mbarara, 1410, UgandaCorrespondence: Joel Bazira, Email jbazira@must.ac.ugBackground: Globally, 10.8 ...
Ndawula C, Petra NP, Wasswa FB, Bazira J
doaj   +4 more sources

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study [PDF]

mBio, 2014
Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis.
Paolo Miotto, Andrea M. Cabibbe, Silke Feuerriegel, Nicola Casali, Francis Drobniewski, Yulia Rodionova, Daiva Bakonyte, Petras Stakenas, Edita Pimkina, Ewa Augustynowicz-Kopeć, Massimo Degano, Alessandro Ambrosi, Sven Hoffner, Mikael Mansjö, Jim Werngren, Sabine Rüsch-Gerdes, Stefan Niemann, Daniela M. Cirillo   +17 more
doaj   +3 more sources

Pyrazinamide resistance in rifampicin discordant tuberculosis. [PDF]

PLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase, Ravesh Singh, Khine Swe Swe-Han, Koleka Patience Mlisana   +3 more
doaj   +3 more sources

Association between overexpression of efflux pumps genes Rv0191 and Rv3008 and pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis: a multi-center study [PDF]

BMC Infectious Diseases
Background Pyrazinamide is a drug that helps shorten the duration of tuberculosis treatment. Mutations in the pncA are the most common mechanism of pyrazinamide resistance in M. tuberculosis.
Mohammad Hashemzadeh, Sadegh Hamid, Azar Dokht Khosravi, Saman Soleimanpour, Mohammad Savari   +4 more
doaj   +2 more sources

Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients

International Journal of Mycobacteriology
Background: All-oral regimens, including bedaquiline, are now standard in shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB). Resistance or intolerance to drugs in STR often necessitates a switch to longer treatment regimens (
Oki Nugraha Putra, Nur Indah, Telly Purnamasari, Adi Larasanti   +3 more
doaj   +2 more sources

Predicting pyrazinamide resistance in Mycobacterium tuberculosis using a graph convolutional network [PDF]

BMC Microbiology
Background Pyrazinamide is an important first-line antibiotic for treating tuberculosis, with resistance primarily driven by mutations in the pncA gene. Traditional machine learning models are able to predict pyrazinamide resistance with some success but
Dylan Dissanayake, Viktoria Brunner, Dylan Adlard, Joseph A. Morrone, Philip W. Fowler   +4 more
doaj   +2 more sources

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015

International Journal of Mycobacteriology, 2017
Background: The first line anti-tuberculosis drug pyrazinamide (PZA) is important when treating PZA susceptible multidrug-resistant tuberculosis (MDR-TB). Several drug resistance surveys have however reported PZA resistance among a significant proportion
Mikael Mansjo, Jim Werngren, Sven Hoffner   +2 more
doaj   +2 more sources

Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolatesPncA mutations and PZA resistance in M. tuberculosis in Vietnam [PDF]

Emerging Microbes and Infections, 2017
Pyrazinamide (PZA) is a key antibiotic in current anti-tuberculosis regimens. Although the WHO has stressed the urgent need to obtain data on PZA resistance, in high tuberculosis burden countries, little is known about the level of PZA resistance, the ...
Nguyen Quang Huy, Contamin Lucie, Tran Thi Thanh Hoa, Nguyen Van Hung, Nguyen Thi Ngoc Lan, Nguyen Thai Son, Nguyen Viet Nhung, Dang Duc Anh, Bañuls Anne-Laure, Nguyen Thi Van Anh   +9 more
doaj   +2 more sources

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania [PDF]

BMC Infectious Diseases, 2019
Background Tuberculosis (TB) is the leading cause of death from an infectious disease and the roll-out of rapid molecular diagnostics for rifampin resistance has resulted in a steady rise in the number of patients with multidrug-resistant (MDR)-TB ...
Saumu Pazia Juma, Athanasia Maro, Suporn Pholwat, Stellah G. Mpagama, Jean Gratz, Alphonse Liyoyo, Eric R. Houpt, Gibson S. Kibiki, Blandina T. Mmbaga, Scott K. Heysell   +9 more
doaj   +2 more sources

Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan [PDF]

BMC Infectious Diseases, 2019
Background Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB).
Muhammad Tahir khan, Shaukat Iqbal Malik, Sajid Ali, Nayyer Masood, Tariq Nadeem, Anwar Sheed Khan, Muhammad Tanvir Afzal   +6 more
doaj   +2 more sources